Donga Socio Holdings - Asset Resilience Ratio
Donga Socio Holdings (000640) has an Asset Resilience Ratio of 1.85% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2024)
This chart shows how Donga Socio Holdings's Asset Resilience Ratio has changed over time. Check Donga Socio Holdings strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Donga Socio Holdings's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 000640 market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩37.95 Billion | 1.85% |
| Total Liquid Assets | ₩37.95 Billion | 1.85% |
Asset Resilience Insights
- Limited Liquidity: Donga Socio Holdings maintains only 1.85% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Donga Socio Holdings Industry Peers by Asset Resilience Ratio
Compare Donga Socio Holdings's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423 |
Drug Manufacturers - Specialty & Generic | 20.44% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 48.48% |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535 |
Drug Manufacturers - Specialty & Generic | 11.69% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 4.31% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 15.57% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 18.70% |
Annual Asset Resilience Ratio for Donga Socio Holdings (2000–2024)
The table below shows the annual Asset Resilience Ratio data for Donga Socio Holdings.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.49% | ₩9.95 Billion ≈ $6.75 Million |
₩2.03 Trillion ≈ $1.38 Billion |
-1.59pp |
| 2023-12-31 | 2.08% | ₩40.64 Billion ≈ $27.54 Million |
₩1.96 Trillion ≈ $1.33 Billion |
+1.46pp |
| 2022-12-31 | 0.61% | ₩10.63 Billion ≈ $7.20 Million |
₩1.73 Trillion ≈ $1.17 Billion |
-2.86pp |
| 2021-12-31 | 3.48% | ₩58.84 Billion ≈ $39.87 Million |
₩1.69 Trillion ≈ $1.15 Billion |
-0.21pp |
| 2020-12-31 | 3.68% | ₩55.67 Billion ≈ $37.73 Million |
₩1.51 Trillion ≈ $1.02 Billion |
-0.35pp |
| 2019-12-31 | 4.03% | ₩54.81 Billion ≈ $37.14 Million |
₩1.36 Trillion ≈ $920.69 Million |
+3.56pp |
| 2018-12-31 | 0.48% | ₩5.93 Billion ≈ $4.02 Million |
₩1.24 Trillion ≈ $841.64 Million |
+0.40pp |
| 2017-12-31 | 0.08% | ₩1.11 Billion ≈ $749.55K |
₩1.46 Trillion ≈ $989.05 Million |
-0.10pp |
| 2016-12-31 | 0.17% | ₩2.43 Billion ≈ $1.65 Million |
₩1.40 Trillion ≈ $950.26 Million |
-0.13pp |
| 2015-12-31 | 0.30% | ₩3.70 Billion ≈ $2.51 Million |
₩1.22 Trillion ≈ $829.16 Million |
+0.09pp |
| 2014-12-31 | 0.21% | ₩2.25 Billion ≈ $1.52 Million |
₩1.08 Trillion ≈ $732.63 Million |
-0.52pp |
| 2013-12-31 | 0.73% | ₩7.20 Billion ≈ $4.88 Million |
₩988.28 Billion ≈ $669.74 Million |
+0.52pp |
| 2012-12-31 | 0.21% | ₩3.59 Billion ≈ $2.43 Million |
₩1.72 Trillion ≈ $1.17 Billion |
-2.77pp |
| 2011-12-31 | 2.98% | ₩44.45 Billion ≈ $30.12 Million |
₩1.49 Trillion ≈ $1.01 Billion |
+2.16pp |
| 2010-12-31 | 0.82% | ₩10.09 Billion ≈ $6.84 Million |
₩1.23 Trillion ≈ $836.45 Million |
+0.66pp |
| 2009-12-31 | 0.16% | ₩1.69 Billion ≈ $1.14 Million |
₩1.06 Trillion ≈ $716.50 Million |
-0.43pp |
| 2008-12-31 | 0.59% | ₩4.52 Billion ≈ $3.06 Million |
₩769.94 Billion ≈ $521.78 Million |
-0.37pp |
| 2007-12-31 | 0.96% | ₩6.83 Billion ≈ $4.63 Million |
₩713.72 Billion ≈ $483.68 Million |
+0.05pp |
| 2006-12-31 | 0.91% | ₩6.62 Billion ≈ $4.49 Million |
₩731.74 Billion ≈ $495.89 Million |
-0.35pp |
| 2005-12-31 | 1.25% | ₩9.08 Billion ≈ $6.15 Million |
₩724.29 Billion ≈ $490.84 Million |
+0.04pp |
| 2004-12-31 | 1.21% | ₩8.56 Billion ≈ $5.80 Million |
₩706.01 Billion ≈ $478.45 Million |
-1.10pp |
| 2003-12-31 | 2.31% | ₩15.98 Billion ≈ $10.83 Million |
₩691.41 Billion ≈ $468.56 Million |
+0.08pp |
| 2002-12-31 | 2.23% | ₩13.18 Billion ≈ $8.93 Million |
₩590.72 Billion ≈ $400.32 Million |
-2.21pp |
| 2001-12-31 | 4.44% | ₩26.35 Billion ≈ $17.86 Million |
₩593.63 Billion ≈ $402.30 Million |
+0.49pp |
| 2000-12-31 | 3.95% | ₩21.63 Billion ≈ $14.66 Million |
₩547.36 Billion ≈ $370.94 Million |
-- |
About Donga Socio Holdings
Dong-A Socio Holdings Co., Ltd., together with its subsidiaries, engages in the pharmaceutical business in South Korea. It operates through Holding Company; Over-the-Counter Drugs and Quai-Drugs; Biosimilars and Consignment Medicines; Logistics; Packaging Solutions; and Others segments. The company develops DA-8010 in Phase 3 clinical trial to treat overactive bladder; DMB-3115, a biosimilar of S… Read more